syringe astrazeneca will now charge a price for the COVID-19 vaccine, abandoning the not-for-profit model it started at the start of the pandemic. Poor countries will be excluded from this as Pascal Soriot, CEO of the pharmaceutical company, justified the change by noting that Covid-19 will soon enter it is "endemic phase".